At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 24 enrolled
Drug / intervention
Secnidazole 2 GM Oral Granulesdrug
Likely dose
Secnidazole 2 GM Oral Granules 2gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study
In Brief
A Phase 3 clinical trial evaluating Secnidazole 2 GM Oral Granules for Recurrent Bacterial Vaginosis. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of this study is to test the effectiveness Secnidazole to treat recurrent BV. Secnidazole is approved for one-time use in acute BV. In this study, the drug will be used for recurrent BV, and given weekly for 18 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Bacterial Vaginosis
CountriesUnited States
CollaboratorsLupin Pharmaceuticals, Inc.
Timeline
Phase 3CompletedFinished
20222023202420252026
Enrollment StartJul 2021
First PostedSep 2021
Primary CompletionOct 2022
TodayJul 2026
First PostedSep 5, 2021
Enrollment StartJul 9, 2021
Primary CompletionOct 7, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.8 years ago
Interventions
Secnidazole 2 GM Oral Granulesdrug
Once weekly 2g oral secnidazole for 18 weeks